Ocular Therapeutix
OCUL
73 hedge funds and large institutions have $170M invested in Ocular Therapeutix in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 10 closing their positions.
99% more call options, than puts
Call options by funds: $2.98M | Put options by funds: $1.5M
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
17% more capital invested
Capital invested by funds: $146M → $170M (+$24.6M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 76 → 73 (-3)
6.12% less ownership
Funds ownership: 69.91% → 63.79% (-6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.7M |
| 2 |
CCI
Columbus Circle Investors
|
+$5.14M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.8M |
| 4 |
JP Morgan Chase
New York
|
+$3.05M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.5M |
| 2 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$3.38M |
| 3 |
B
Bailard
Foster City,
California
|
-$833K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$605K |
| 5 |
CI
Cowen Inc
New York
|
-$597K |
OCUL Hedge Fund Activity: Q1 2017 in Review
73 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2017, worth a combined $170M — up 17% from $146M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OCUL positions and 10 closed out — a net gain of 2 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $10.7M. The largest seller was Fidelity Investments, cutting an estimated $10.5M.
- 73 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2017, down from 76 in Q4 2016.
- Funds reported $170M of Ocular Therapeutix stock for Q1 2017, up 17% quarter-over-quarter.
- 12 funds opened new Ocular Therapeutix positions in Q1 2017 and 10 closed out, a net change of +2 holders.
- The largest Ocular Therapeutix buyer in Q1 2017 was BlackRock, an estimated $10.7M added.
- The largest Ocular Therapeutix seller in Q1 2017 was Fidelity Investments, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2017.